Abstract:Background Epigenetic alternation is a common contributing factor to neoplastic transformation. Although previous studies have reported a cluster of aberrant promoter methylation changes associated with silencing of tumor suppressor genes, little is known concerning their sequential DNA methylation changes during the carcinogenetic process. The aim of the present study was to address a genome-wide search for identifying potentially important methylated changes and investigate the onset and pattern of methylation changes during the progression of colorectal neoplasia. Methods A three-phase design was employed in this study. In the screening phase, DNA methylation profile of 12 pairs of colorectal cancer (CRC) and adjacent normal tissues was analyzed by using the Illumina MethylationEPIC BeadChip. Significant CpG sites were selected based on a cross-validation analysis from The Cancer Genome Atlas (TCGA) database. Methylation levels of candidate CpGs were assessed using pyrosequencing in the training dataset (tumor lesions and adjacent normal tissues from 46 CRCs) and the validation dataset (tumor lesions and paired normal tissues from 13 hyperplastic polyps, 129 adenomas, and 256 CRCs). A linear mixed-effects model was used to examine the incremental changes of DNA methylation during the progression of colorectal neoplasia. Results The comparisons between normal and tumor samples in the screening phase revealed an extensive CRC-specific methylomic pattern with 174,006 (21%) methylated CpG sites, of which 22,232 (13%) were hyermethylated and 151,774 (87%) were hypomethylated. Hypermethylation mostly occurred in CpG islands with an overlap of gene promoters, while hypomethylation tended to be mapped far away from functional regions. Further cross validation analysis from TCGA dataset confirmed 265 hypermethylated promoters coupling with downregulated gene expression. Among which, hypermethylated changes in MEEPD2 promoter was successfully replicated in both training and validation phase. Significant hypermethylation appeared since precursor lesions with an extensive modification in CRCs. The linear mixed-effects modeling analysis found that a cumulative pattern of MPPED2 methylation changes from normal mucosa to hyperplastic polyp to adenoma, and to carcinoma ( P < 0.001). Conclusions Our findings indicate that epigenetic alterations of MPPED2 promoter region appear sequentially during the colorectal neoplastic progression. It might be able to serve as a promising biomarker for early diagnosis and stage surveillance of colorectal tumorigenesis.

Transcriptional Inactivation of ERβ Gene Is Mediated by the Induction of Promoter Hypermethylation in a Rat Colonic Epithelial Cell Model

Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer

Promoter hypermethylation of GALR1 acts as an early epigenetic susceptibility event in colorectal carcinogenesis

Epigenetic Regulation of the ERβ Gene on the Estrogen Signal Transfection Pathway in Colon Cancer Cells

Inhibition of the Extracellular Signal-Regulated Kinase/mitogen-Activated Protein Kinase Pathway Decreases DNA Methylation in Colon Cancer Cells.

Expression of Estrogen Receptor Β Isoforms in Normal Breast Epithelial Cells and Breast Cancer: Regulation by Methylation

OPCML is Frequently Methylated in Human Colorectal Cancer and Its Restored Expression Reverses EMT Via Downregulation of Smad Signaling.

Prolonged Stimulation with Tumor Necrosis Factor-Alpha Induced Partial Methylation at PR-B Promoter in Immortalized Epithelial-Like Endometriotic Cells.

Short Hairpin RNA Causes the Methylation of Transforming Growth Factor-Β Receptor II Promoter and Silencing of the Target Gene in Rat Hepatic Stellate Cells

Retinoid X Receptor-α Expression Suppression and its Promoter Methylation Associates with β-catenin Expression in Colorectal Cancer

Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation

Novel Role of Macrophage in the Induction of Th2 Immunity

Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2

Epigenetic Silencing Oflrrc3bin Colorectal Cancer

Estrogen Receptor Β Promoter Methylation: a Potential Indicator of Malignant Changes in Breast Cancer.

DNA Methylation of the Promoter of Soluble Epoxide Hydrolase Silences Its Expression by an SP-1-dependent Mechanism.

Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells

Regulation of ERRP-induced Inhibition of Proliferation in HCT-116 Colon Cancer Cell Line

Oestrogen Receptor Β Regulates Epigenetic Patterns at Specific Genomic Loci Through Interaction with Thymine DNA Glycosylase

[Transcription Regulation of 5-Aza-2'-deoxycytidine on Maspin Gene Demethylation in RKO Human Colorectal Cell Line].

Specific Reversal of Tumor-Suppressor Gene Promoter Hypermethylation with Bovine Oocyte Extract